Bio-Rad said it is withdrawing its previously issued annual revenue guidance given the uncertainties regarding the duration and impact of the COVID-19 pandemic.
The firm said it can produce enough viral RNA extraction reagents to support more than 7 million real-time PCR tests per month for detecting SARS-CoV-2.
The added funds will be used by Tangen to develop a molecular diagnostic platform to detect anthrax in the bloodstream and develop infectious disease tests.
Fulgent saw a 75 percent increase year over year in billable tests, leading to revenues of $7.8 million. It also withdrew its 2020 full-year revenue guidance.
Among the study's aims is determining how rates of SARS-CoV-2 infection differ between healthy children and ones with asthma or other allergic conditions.
The rapid automated RT-PCR test detects SARS-CoV-2 from nasopharyngeal, oropharyngeal, or nasal swab specimens and runs on NeuMoDx's Molecular Systems.
The RT-PCR-based test kit is designed to detect the RdRp and E genes of the virus in various respiratory specimens including nasopharyngeal swabs and sputum.
Nobel laureates and scientific societies urge NIH and the Department of Health and Human Services to revisit the recent decision to end funding for a coronavirus grant.
In Science this week: machine learning algorithm for faster Mendelian disorder diagnoses, gene linked to safe response to nitrogen-containing bisphosphonates, and more.
